In 2014, the PARADIGM-HF trial introduced the first of its kind angiotensin receptor-neprilysin inhibitor (ARNI), sacubitril/valsartan, which exerts its function by a dual mechanism, namely, angiotensin receptor blockage and NEP inhibition (12). This evidence concerns the gene MME and hydrops fetalis.